Dr. Robert Cameron Chairs International Panel of Medical Specialists at 4th Annual Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma
The Pacific Meso Center, in conjunction with The Office of Continuing Medical Education of the David Geffen School of Medicine at UCLA, held the 4th International Symposium on Lung-SparingTherapies for Malignant Pleural Mesothelioma on June 7, 2014 in Santa Monica, California. The Worthington & Caron was proud to once again be a platinum sponsor of this unique medical seminar focusing on rational treatment options for patients with pleural mesothelioma.
As in years past, the course organizer and chair of the symposium was thoracic surgeon and pleural mesothelioma specialist, Dr. Robert Cameron. An ardent supporter of rational lung-sparing treatments for pleural mesothelioma, and innovator of the pleurectomy/decortication (“PD”) surgical procedure, Dr. Cameron is the founder and director of both the Comprehensive Mesothelioma Program at the UCLA Medical Center and the Mesothelioma Treatment Center of Excellence at the West Los Angeles Veterans’ Administration Medical Center.
Dr. Cameron discussed how, because of the diffuse nature of mesothelioma tumors, there is no advantage to removing the lung via extrapleural pneumonectomy (“EPP”), a radical surgery which involves removal of the pleura-based tumor along with the adjacent lung, diaphragm and portions of the pericardium. Dr. Cameron explained that, as compared to lung-sparing PD, “there are consequences to extending the surgical field with EPP.” Dr. Cameron pointed to statistics revealing a greater rate of “distant” tumor recurrence associated with EPP. He noted that “distant” recurrences in areas such as the peritoneum are more difficult to treat than “local” recurrences at or near the tumor bed.
In a second presentation, Dr. Cameron addressed the latest developments in intraoperative therapies to attack disease at a cellular level through chemicals such as Betadine, as well as chemotherapy, thermal therapies, light therapies and immune therapies.
Dr. Olga Olevsky , Oncologist and member of the Comprehensive Mesothelioma Program at UCLA, addressed the topic of when is the optimal time to administer Pemetrexed/Cisplatin or Pemetrexed/Carboplatin chemotherapy—before, during or after surgery. She presented the results of studies revealing that there is no statistical advantage to any of the three protocols, but posited that there may be advantages to adjuvant or postoperative administration of chemotherapy because it allows more aggressive initial treatment via surgery and allows for more accurate monitoring of response.
Dr. Percy Lee, Chief of Thoracic Radiation Oncology and member of the Comprehensive Mesothelioma Program at UCLA Medical Center, gave an informative presentation on postoperative tomotherapy following PD. Dr. Lee explained how he and his team at UCLA work closely with Dr. Cameron to maximize effective delivery of radiation and minimize the risk of radiation toxicity utilizing the latest tomography technology.
A timely presentation regarding the challenges of treating veterans, who are disproportionally affected by mesothelioma, in the world’s largest healthcare system, and how the Mesothelioma Treatment Center of Excellence at the West Los Angeles VA Medical Center has overcome these challenges was provided by Graciela Hoal, RN, NP.
Dr. Irene I-Lan Wu, Assistant Director of the UCLA Pain Management Center, gave a presentation regarding recent developments in postoperative pain management therapies including intrathecal drug delivery and spinal cord stimulators.
International presenters, Dr. Jan von MeerBeeck, Professor of Thoracic Oncology and Director of Thoracic Oncology at the University of Antwerp, Belgium, and Dr. Joachim Aerts, Chief of Thoracic Oncology at Erasmus Cancer Institute in Rotterdam, Netherlands, gave presentations on recent studies involving state-of-the-art targeted therapies for advanced/inoperable mesothelioma and dendritic cell based immunotherapy.
Updates regarding research into innovative mesothelioma therapies involving mesenchymal stem cells and genes and molecular mechanisms being conducted at the Pacific Meso Center were provided by Research Scientists Raymond Wong, PhD and Irina Ianculescu, PhD.
International presenters, Dr. Jan von MeerBeeck, Professor of Thoracic Oncology and Director of Thoracic Oncology at the University of Antwerp, Belgium, and Dr. Joachim Aerts, Chief of Thoracic Oncology at Erasmus Cancer Institute in Rotterdam, Netherlands, gave presentations on recent studies involving state-of-the-art targeted therapies for advanced/inoperable mesothelioma and dendritic cell based immunotherapy.
Updates regarding research into innovative mesothelioma therapies involving mesenchymal stem cells and genes and molecular mechanisms being conducted at the Pacific Meso Center were provided by Research Scientists Raymond Wong, PhD and Irina Ianculescu, PhD.
